C is the healthcare company most prolific at making international expansions, followed by Takeda Pharmaceutical and Fresenius SE & Co. GlobalData’s healthcare foreign direct investment (FDI) company report highlights the current foreign investments made by leading healthcare investors. Buy the report here.
C has been the most active healthcare greenfield investor between Q1 2019 and Q3 2023, according to GlobalData’s FDI Projects Database.
Greenfield foreign direct investment is when a company invests abroad to establish a new physical presence or expand an existing operation. Greenfield investments create jobs and/or involve a capital investment into the foreign location. Other forms of FDI, such as mergers and acquisitions, are not included as part of this definition.
The majority of C investments were in the medical practice management and services subsector. In fact, 87.6% of its total foreign investments were in this subsector. It also created projects across a further 4 subsectors.
By business function, most (85.6%) of C projects were related to healthcare provision.
The company has been active across six world regions, mainly focused on North America which received 86.6% of the company’s greenfield investments between Q1 2019 and Q3 2023. Its top three destination countries (by number of greenfield FDI projects) were the US, Puerto Rico and Seychelles. Combined these three countries account for 103.5% of its total number of healthcare investments.
C created more FDI projects in 2021 compared to any other year between Q1 2019 and Q3 2023.
Australia is the leading source market for outbound healthcare greenfield FDI projects. The country accounts for 16% of total outbound healthcare investment projects. There have been 5 unique parent companies from Australia that have announced healthcare FDI projects between between Q1 2019 and Q3 2023.
To further understand the top healthcare FDI companies, access GlobalData’s Top healthcare Foreign Direct Investment Companies report.